Blood samples may unlock secrets of cancer drug resistance
NCT ID NCT05272423
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study collects blood samples from up to 500 adults in the US with KRAS G12C-positive cancer whose disease has progressed after treatment with a KRAS inhibitor. Researchers will analyze the samples to identify genetic changes that cause resistance. The goal is to compare resistance patterns between different drugs and cancer types, which may guide future treatment strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could reveal why some cancers become resistant to KRAS inhibitors, pointing toward better combination treatments.
What could go wrong
This is an observational study, not a treatment trial. It collects data only, so it won't directly help participants. Results may not lead to new therapies quickly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS P.G12C are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States